Pharming Group to participate in June investor conferences
Conference attendancePharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the month of June:
2025
Pharming Group reports first quarter 2025 financial results and provides business update
Financial updatesPharming Group N.V. presents its preliminary unaudited financial report for the three months ended March 31, 2025.
Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director
Corporate updatesPharming Group N.V. announces that the Company’s 2025 Annual General Meeting of Shareholders (the “AGM”) will be held on Wednesday June 11, 2025, at 14:00 CEST.
Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)
Conference attendancePharming Group N.V. announces the following presentations by the Company or its collaborators at the 2025 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 1-4, 2025 in Philadelphia, PA.
Pharming Group to report first quarter 2025 financial results on May 8
Financial updatesPharming Group N.V. confirms it will report its preliminary (unaudited) first quarter 2025 financial results, for the period ended March 31, on Thursday, May 8, 2025.
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
Corporate updatesFor media and investors only
Pharming Group announces the filing of its 2024 Annual Report and Form 20-F
Financial updatesPharming Group N.V. announces the filing of its Annual Report for the year ended December 31, 2024 (the “Period”).
Pharming Group to participate in April investor conferences
Conference attendancePharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the month of April:
Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation
Clinical trialsPharming Group N.V. announces that the first patient has been dosed in a Phase II, proof of concept, clinical trial evaluating leniolisib in common variable immunodeficiency (CVID) patients with immune dysregulation.
Pharming Group reports fourth quarter and full year 2024 financial results and provides business update
Financial updatesPharming Group N.V. presents its preliminary (unaudited) financial report for the three months and full year ended December 31, 2024.